Browsed by
Author: Member Success

Creatv MicroTech Receives DoD Funding for Lung Cancer Screening

Creatv MicroTech Receives DoD Funding for Lung Cancer Screening

ROCKVILLE, MD, September 14, 2018
Creatv MicroTech, Inc. (Creatv) has received a $625,000 award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to investigate their discovery of giant circulating cells found in peripheral blood for non-invasive detection of lung cancer by differentiating malignant from benign pulmonary nodules detected by low dose CT (LDCT). In the three-year study, Creatv will examine blood samples from 1,250 subjects at high risk for lung cancer based on their smoking history and occupational exposure to carcinogens. ...  Read more

SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

GERMANTOWN, Md.Sept. 5, 2018 /PRNewswire/ — SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes. ...  Read more

Veralox Success Story

Veralox Success Story

FREDERICK, Md.Aug. 31, 2018 /PRNewswire-PRWeb/ — Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). ...  Read more

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome

CHICAGOAug. 14, 2018 /PRNewswire/ — Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age. ...  Read more

BIO Investor Forum

BIO Investor Forum

Program

The BIO Investor Forum delivers a rich program that features corporate presentations and panel debates on the sweet spots and growth challenges facing the industry.  The BIO Investor Forum features: ...  Read more

Announcing the Inova Translational Research Funding Program (ITRF)

Announcing the Inova Translational Research Funding Program (ITRF)

Inova Health System, through the Office of Research and Commercialization, is excited to share with you the launch of a new research funding initiative, the Inova Translational Research Funding Program (ITRF). This program, which will fund cutting-edge translational research across our system, was created to encourage the development of research talent at Inova and to foster interdepartmental, interinstitutional, academic and industry collaborations. We hope that these partnerships will lead to larger research endeavors that advance our mission to help our patients and our community. ...  Read more